SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs informs about updates on acquisition

17 Feb 2024 Evaluate
With reference to disclosures dated May 31, 2023 and July 12, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs 80 Crores and update on payment of Tranche1 subscription amount to ImmunoACT respectively, Laurus Labs has informed that the Company has paid the subscription amount of Rs 32,00,75,184 (Rupees Thirty Two Crores Seventy Five Thousand One Hundred and Eighty Four only) as ‘Tranche 2 (Final) Subscription Amount’. The Shareholding of the Company in ImmunoACT is 33.86% (on a fully-diluted basis).

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

1111.05 -3.45 (-0.31%)
22-Apr-2026 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.60
Dr. Reddys Lab 1220.85
Cipla 1235.35
Zydus Lifesciences 930.00
Lupin 2309.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×